MEXICO CITY, April 1 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. ("Genomma Lab" or "the Company") announced today the purchase of 100% of the shares of Medicinas y Medicamentos Nacionales, S.A.P.I., de C.V., a Mexican company.
Through this new subsidiary, Genomma Lab will sell new product lines within the categories of analgesics, cold remedies, anti-fungal, anti-inflammatory, expectorants and multivitamins, among others.
Genomma Lab will apply its strategy of manufacturing these new product lines through third parties, thereby maintaining the high-quality standards that are characteristic of the Company.
Genomma Lab expects to launch the products applying Genomma's characteristic marketing and sales capabilities of its business model.
For strategic market reasons, Genomma Lab will provide additional details regarding the development of this business during second quarter 2009.
Company Description
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.
Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).
CONTACT: Investors, Oscar Villalobos, Genomma Lab Internacional,
+011-5255-5081-0000, ext. 4250, inversion@genommalab.com; or In New York:
i-advize Corporate Communications, Inc., +1-212-406-3691, +1-212-406-3695,
genomma@i-advize.com
Web site: http://www.genommalab.com/
